Science and Research Content

Kudos and Agenus partner to raise awareness of BOT+BAL immunotherapy research -

Kudos, a research communication platform, has partnered with biotechnology company Agenus to raise awareness of its oncology research, particularly the botensilimab (BOT) and balstilimab (BAL) immunotherapy combination.

Under the partnership, Kudos will host educational content about BOT+BAL, helping oncologists and other healthcare professionals understand how the combination works, the available clinical evidence, and its development progress. Botensilimab is an Fc-enhanced anti-CTLA-4 antibody, while balstilimab is a PD-1 inhibitor developed by Agenus.

The collaboration builds on Kudos' work in research communication, extending its focus on making complex scientific findings more accessible to healthcare professionals and other relevant audiences.

The initiative also includes generative engine optimization (GEO) to improve the visibility of scientific research in AI-powered search results and generated answers. This approach emphasizes clear, well-structured content that helps readers and AI systems discover and interpret research findings.

Click here to read the original press release.

STORY TOOLS

  • |
  • |

sponsor links

For banner adsĀ click here